News

News

Biomedical Enterprise International Development Association (Shanghai) Holds its First General Meeting, Theresa Tse Elected President

Release Date: 2026-11-03

On November 2, Biomedical Enterprise International Development Association (Shanghai) held its first general meeting and establishment ceremony at the Chia Tai Tianqing Global R&D Headquarters. As the first professional social organization in China focusing on the international development of biopharmaceuticals, the association focuses on the pain points and challenges in the internationalization process of Chinese innovative drugs. It brings together leading pharmaceutical companies, professional institutions, and international cooperation resources, and is committed to building an open and shared service platform for industry internationalization to promote the accelerated entry of China's pharmaceutical innovation achievements into the global market.

 

 

In accordance with relevant articles of association, the first general meeting of Biomedical Enterprise Internationalization Development Association (Shanghai) reviewed and approved matters such as the association's charter, election methods, membership fee standards, and management systems, and elected the first council, supervisory board, and leadership bodies. Theresa Tse, Chairman of the Board of SBP Group and Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., was elected as the first President; Chen Qiyu, Co-CEO of Fosun International and Director of Fosun Pharma, Dai Hongbin, Vice Chairman of Hengrui Pharma, and a relevant person in charge from the Shanghai Biomedical Technology Industry Promotion Center were elected as Vice Presidents; Fei Fan, Deputy Secretary of the Party Committee and Managing Partner of the Shanghai office of Ernst & Young Hua Ming LLP, was elected as Chairman of the Supervisory Board.

 

 

 

 

In 2025, the total value of out-licensing deals for China's innovative drugs exceeded 130 billion US dollars, and its new drug pipelines under development accounted for about 30% of the global total, with its innovative R&D strength and international influence continuously increasing. However, issues such as complex overseas registration procedures, difficulties in mutual recognition of clinical data, and insufficient localization resources still constrain the global development of China's innovative drugs.

 

Under the guidance and support of Science and Technology Commission of Shanghai Municipality (STCSM) and other relevant departments, the association was jointly initiated and established by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (a subsidiary of SBP Group), the Shanghai Biomedical Technology Industry Promotion Center, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd. It aims to overcome resource and institutional barriers in the internationalization process of innovative drugs through industry collaboration, and truly transform the R&D advantages of China's innovative drugs into global market competitiveness.

 

 

Eric Tse, Chief Executive Officer of SBP Group and Chairman of Chia Tai Tianqing Pharmaceutical Group, delivered a speech on behalf of the association's President, Theresa Tse. He stated that establishing the association has been a long-term vision for SBP Group and is also an important practice in promoting the internationalization of China's innovative drugs from individual company efforts to industry-wide collaboration. In early 2025, Eric Tse publicly proposed for the first time at the Davos Forum to build a multi-center clinical mutual recognition system in the Asia-Pacific region and along the "Belt and Road", allowing China's innovative drugs to reach global patients faster. Today, this vision is gradually being transformed into an industry cooperation platform. SBP Group is willing to take the lead in opening up its internationalization experience and resources accumulated in Southeast Asia, the Middle East, and along the "Belt and Road", and work with industry partners to build an international collaboration system, allowing more of China's innovative drugs to benefit patients worldwide.

 

 

Currently, the association has attracted more than 50 member units, covering various links in the industrial chain such as innovative R&D, manufacturing, commercialization, and professional services. It brings together leading Chinese pharmaceutical companies such as Chia Tai Tianqing, Hengrui Pharma, Fosun Pharma, Shanghai Pharma, CR Pharma, CSPC Pharmaceutical Group, Junshi Biosciences, and CanSino Biologics, as well as professional institutions like the Shanghai Clinical Innovation and Translation Research Institute and the DIA (Drug Information Association). Focusing on the actual needs of enterprise internationalization, the association has defined its mission as "building a cross-border service platform for biopharmaceutical companies going abroad, integrating Chinese and overseas biopharmaceutical research resources, and promoting the international development of the biopharmaceutical industry." It will focus its work on areas such as policy research, international registration, international multi-center clinical trials, business development, licensing transactions, and market access.

 

 

In the future, the association will focus on "two core mechanisms" to solidly promote enterprises" overseas expansion. First is to focus on establishing a "product white list" to select products that are clinically urgently needed in overseas target markets and have excellent data in China, promoting the accelerated entry of high-quality innovative achievements into the international market. Second is to establish a "multi-center clinical hospital white list" to build a regional clinical collaboration network by uniting high-quality medical institutions at home and abroad, promoting broader international recognition of Chinese clinical data. Meanwhile, the association will focus on promoting the following work: advancing regulatory alignment to accelerate the registration and marketing of innovative products in overseas target markets, and promoting mutual trust and recognition in regulation; consolidating China's experience to transform the overseas expansion paths of leading enterprises into replicable and scalable industry paradigms; building a clinical collaboration network to reduce the costs and improve the R&D efficiency for companies going abroad, etc.

 

During the conference, a representative from the China Society for Drug Regulation gave a special presentation on "The History and Future Vision of China's Drug Regulation Internationalization"; Yang Yue, a researcher from the Department of Pharmacology and Pharmaceutical Sciences at Tsinghua University, analyzed the opportunities and challenges facing the internationalization of China's innovative drugs in a presentation titled "Policy Games and Focus Points in the Internationalization and Overseas Expansion of Innovative Drugs".

 

Zhang Xi, Deputy Director of the China (Shanghai) Pilot Free Trade Zone Administration and Director of the Bonded Area Management Bereau, and Director of the Shanghai Eastern Hub International Business Cooperation Zone Administration; Jiang Ge, Deputy Director of the Shanghai Science and Technology Commission; and Hua Yingzi, Member of the Standing Committee of the CPC Minhang District Committee and Executive Deputy District Mayor of Minhang District, Shanghai, attended the meeting.

 

 

Declaration:

 

The copyright of this article is owned by the original author or the Company. It may not be used by reprinting, copying, filming, adapting, compiling, or other means without authorization. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.

Share: